
|Videos|December 6, 2017
Dr. Barrientos Discusses Ibrutinib in Elderly Populations With CLL
Author(s)Jacqueline C. Barrientos, MD
Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses ibrutinib (Imbruvica) in elderly populations with CLL.
Advertisement
Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses ibrutinib (Imbruvica) in elderly populations with chronic lymphocytic leukemia (CLL).
The 3-year follow-up of the registration trial of ibrutinib in elderly patients with CLL showed promising response rates, says Barrientos, making it her go-to drug for this population.
Additionally, combinations with ibrutinib are in the pipeline, such as ibrutinib plus obinutuzumab (Gazyva).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5



































